Evotec and Bayer enter into multi-target alliance to fight endometriosis

Evotec AG that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-and-bayer-enter-into-multi-target-alliance-to-fight-endometriosis-5602

Weiterlesen

Evotec and Aspireo enter into strategic advisory agreement

Evotec AG and Aspireo Pharmaceuticals Limited an Israeli biopharmaceutical company focused on the development of a novel somatostatin analogue, announced today that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo’s Somatoprim. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-aspireo-enter-into-strategic-advisory-agreement-5079

Weiterlesen

NIH awards major contract to Evotec to Manage and Operate a Small Molecule Repository

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/nih-awards-major-contract-to-evotec-to-manage-and-operate-a-small-molecule-repository-5075

Weiterlesen

CureBeta, a collaboration between Evotec and Harvard University enters strategic alliance with Janssen Pharmaceuticals

Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/curebeta-a-collaboration-between-evotec-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5067

Weiterlesen

CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals

Evotec AG today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/curebeta-a-collaboration-between-evotec-ag-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5600

Weiterlesen